Over the past few years, there has been a significant change in the model for driving biotech innovation. The complexities and rising costs of developing new medicines and health products have necessitated a collaborative and risk-sharing approach to R&D. As a result, a more intricate web of players is now involved in the game. Read More
Moving into a chronic indication with numerous approved drugs is a challenge that gives pause to drugmakers, even when millions of patients can't tolerate or don't respond to existing therapies. When the indication additionally falls into the central nervous system (CNS) space, which has bedeviled dozens of drug development attempts in recent years, all but the boldest in the field tend to focus their efforts elsewhere. Read More
